Q1 2026 Innovative Drug BD Transactions Surpass $60 Billion! Hang Seng Innovative Drug ETF Huatai-PineBridge (520500) Trading Volume Significantly Increased

Against the backdrop of ongoing market fluctuations and divergence in China’s A-share market, along with continued pullbacks in technology and growth sectors, the innovative drug sector—benefiting from policy tailwinds and turning-point performance—has seen a significant boost in appeal. The innovative drug concept has surged against the trend, becoming one of the key main storylines drawing current market attention. In today’s early session, the innovative drug sector has continued to rebound, and related ETFs have seen brisk trading activity.

According to Wind data, the only ETF product tracking the Hang Seng Innovation Drug Index across the entire market is the Hang Seng Innovation Drug ETF Huatai-PineBridge (520500). Its trading volume has recently surged significantly. As of the latest figures, over the past two trading days, the ETF’s trading amounts have reached 1.4 billion yuan and 1.7 billion yuan, respectively, compared with an average daily trading amount of 560 million yuan since 2026. The expansion trend is clear. Since the end of February this year, cumulative net inflows have totaled 146 million yuan. The latest fund size has risen to 2.156 billion yuan, setting a new all-time high.

The explosive growth in business development (BD) transactions with external parties has become the direct catalyst for this round of market action. On March 28, the National Medical Products Administration (NMPA) released information showing that in the first quarter of 2026, the total value of innovation-drug BD transactions in China has already surpassed USD 60 billion, approaching half of the total for all of 2025. The number of transactions was 53, with upfront payments exceeding USD 3.3 billion. Both scale and growth rate have set new highs for the same period in history.

Policy tailwinds continue to be released. In the 2026 “Government Work Report,” for the first time, bio-medicine is explicitly listed as an “emerging pillar industry,” placed alongside industries such as integrated circuits and aerospace, signaling the core position of the innovation-drug industry within the national team—upgrading from “encouraging development” to “key support.”

On the data catalyst front, since March, innovation drugs have entered a dense period of international academic conferences. The European Lung Cancer Conference (ELCC) was already held on March 25. The annual meetings of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) are scheduled to take place successively in April and May. At that time, many Chinese pharmaceutical companies are expected to disclose clinical data for innovative drugs, which could further enhance pipeline value and BD opportunities, becoming an important catalyst for attracting capital to position ahead of time.

As the only ETF currently tracking the Hang Seng Innovation Drug Index, the Hang Seng Innovation Drug ETF Huatai-PineBridge (520500) invests in 40 Hong Kong-listed innovation-drug leaders through the QDII mechanism. It mainly focuses on upstream and midstream innovation-drug segments such as biopharmaceuticals, chemical pharmaceuticals, and APIs. The ETF brings together a group of industry leaders with strong R&D capabilities and development potential. With a relatively large scale and better liquidity, and with support for in-market T+0 trading, amid the divergence in technology and cyclical market conditions and the high-to-low switching of capital, it is expected to become an efficient tool to help capital rebalance and seize opportunities in Hong Kong-listed innovative drug investments.

Huatai-PineBridge, as one of the first ETF managers in the market, has deep expertise in index investing for nearly 20 years, and has built products such as the market’s first dividend-themed ETF and the first cross-market ETF. As of the end of 2025, in the past two years, the ETFs under the company have generated more than RMB 164 billion in profit for holders, making it one of only four fund companies in the whole market that recorded cumulative profits exceeding RMB 100 billion in the same period. Regarding fees, 77.8% of the ETF products by scale under the company adopt the lowest fee tier structure currently available for equity index fund products (management fee rate 0.15% per year + custody fee rate 0.05% per year).

The Beijing Youth Daily